

## Inhibitoren des Komplementsystems: Erweiterung des therapeutischen Spektrums steht vor der Tür

1. Schmidt CQ, Lambris JD, Ricklin D. Protection of host cells by complement regulators. *Immunol.Rev.* 2016;274:152-171.
2. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. *Blood* 2013;121:4985-4996.
3. Amara U, Rittirsch D, Flierl M et al. Interaction between the coagulation and complement system. *Adv.Exp.Med.Biol.* 2008;632:71-79.
4. Luzzatto L. Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-cell mosaicism. *Curr.Opin.Genet. Dev.* 2006;16:317-322.
5. Hernandez-Campo PM, Almeida J, Acevedo MJ et al. Detailed immunophenotypic characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria. *Transfusion* 2008;48:1403-1414.
6. Richards SJ, Hillmen P. Immunophenotypic analysis of PNH cells. *Curr.Protoc.Cytom.* 2002;Chapter 6:Unit.
7. Nebe T, Schubert, J. et al. Flow cytometric analysis of GPI-deficient cells for the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). *J.Lab.Med.* 2003;27:257-265.
8. Hochsmann B, Rojewski M, Schrezenmeier H. Paroxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes. *Ann.Hematol.* 2011;90:887-899.
9. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. *N.Engl.J.Med.* 1995;333:1253-1258.
10. de Latour RP, Mary JY, Salanoubat C et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. *Blood* 2008;112:3099-3106.
11. Socie G, Mary JY, De Gramont A et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. *Lancet* 1996;348:573-577.
12. Brodsky RA, Young NS, Antonioli E et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. *Blood* 2008;111:1840-1847.
13. Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. *N.Engl.J.Med.* 2004;350:552-559.
14. Hillmen P, Muus P, Dührsen U et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. *Blood* 2007;110:4123-4128.
15. Schubert J, Hillmen P, Röth A et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. *Br.J.Haematol.* 2008
16. Hill A, Hillmen P, Richards SJ et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. *Blood* 2005;106:2559-2565.
17. Harder MJ, Kuhn N, Schrezenmeier H et al. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. *Blood* 2017;129:970-980.
18. Hochsmann B, Leichtle R, von Zabern I et al. Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test. *Vox Sang.* 2012;102:159-166.
19. Hill A, Rother RP, Arnold L et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. *Haematologica* 2010;95:567-573.
20. Risitano AM, Notaro R, Marando L et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. *Blood* 2009;113:4094-4100.
21. Luzzatto L, Risitano AM, Notaro R. Paroxysmal nocturnal hemoglobinuria and eculizumab. *Haematologica* 2010;95:523-526.
22. Risitano AM, Notaro R, Luzzatto L et al. Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab. *N.Engl.J.Med.* 2010;363:2270-2272.
23. Kristiansen M, Graversen JH, Jacobsen C et al. Identification of the haemoglobin scavenger receptor. *Nature* 2001;409:198-201.
24. Olson JS, Foley EW, Rogge C et al. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. *Free Radic.Biol. Med.* 2004;36:685-697.

25. Schnog JJ, Jager EH, van der Dijs FP et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. *Ann.Hematol.* 2004;83:371-375.
26. Hill A, Rother RP, Wang X et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. *Br.J.Haematol.* 2010;149:414-425.
27. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. *JAMA* 2005;293:1653-1662.
28. Olsen SB, Tang DB, Jackson MR et al. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. *Circulation* 1996;93:327-332.
29. Studt JD, Hovinga JA, Furlan M, Lammle B. Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. *Blood* 2003;102:1148.
30. Schafer A, Wiesmann F, Neubauer S et al. Rapid regulation of platelet activation in vivo by nitric oxide. *Circulation* 2004;109:1819-1822.
31. Matejovic M, Krouzecky A, Radej J et al. Coagulation and endothelial dysfunction during longterm hyperdynamic porcine bacteremia-- effects of selective inducible nitric oxide synthase inhibition. *Thromb.Haemost.* 2007;97:304-309.
32. Gralnick HR, Vail M, McKeown LP et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. *Br.J.Haematol.* 1995;91:697-702.
33. Wiedmer T, Hall SE, Ortel TL et al. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. *Blood* 1993;82:1192-1196.
34. Hugel B, Socie G, Vu T et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. *Blood* 1999;93:3451-3456.
35. Ploug M, Plesner T, Ronne E et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. *Blood* 1992;79:1447-1455.
36. Helley D, de Latour RP, Porcher R et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. *Haematologica* 2010;95:574-581.
37. Grunewald M, Siegemund A, Grunewald A et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. *Blood Coagul.Fibrinolysis* 2003;14:685-695.
38. Kelly RJ, Hill A, Arnold LM et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. *Blood* 2011;117:6786-6792.
39. Socie G, Schrezenmeier H, Muus P et al. Changing prognosis in paroxysmal nocturnal haemoglobinuria disease subcategories: an analysis of the International PNH Registry. *Intern.Med.J.* 2016;46:1044-1053.
40. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. *N.Engl.J.Med.* 2009;361:1676-1687.
41. Nurnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. *N.Engl.J.Med.* 2009;360:542-544.
42. Kose O, Zimmerhackl LB, Jungrauthmayr T, Mache C, Nurnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. *Semin.Thromb.Hemost.* 2010;36:669-672.
43. Legendre, C., Babu, S., Furman, R., and et al. Safety and efficacy of eculizumab in aHUS patients resistant to plasma therapy: Interim analysis from a Phase II trial. Abstract presented at the 43rd annual meeting of the American Society of Nephrology, Denver, CO, November 16-21, 2010. Available from: [http://www.abstracts2view.com/asn/view.php?nu=ASN10L1\\_1338a&terms](http://www.abstracts2view.com/asn/view.php?nu=ASN10L1_1338a&terms) . 2011.
44. Muus, P., Legendre, C., Douglas, K., and et al. Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: Interim analysis from a Phase II trial. Abstract presented at the 43rd annual meeting of the American Society of Nephrology, Denver, CO, November 16-21, 2010. Available from: [http://www.abstracts2view.com/asn/view.php?nu=ASN10L1\\_157a&terms](http://www.abstracts2view.com/asn/view.php?nu=ASN10L1_157a&terms) . 2011.
45. Licht C, Greenbaum LA, Muus P et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. *Kidney Int.* 2015;87:1061-1073.
46. Howard JF, Jr., Utsugisawa K, Benatar M et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;16:976-986.

47. Biglarnia AR, Nilsson B, Nilsson T et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. *Transpl.Int.* 2011;24:e61-e66.
48. West-Thielke P, Progar K, Campara M et al. Eculizumab for Prevention of Antibody-Mediated Rejection in Blood Group-Incompatible Renal Transplantation. *Transplant.Proc.* 2018;50:66-69.
49. Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation-a case report. *Transplant.Proc.* 2011;43:2097-2101.
50. Lanfranco L, Joly M, Del BA et al. Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation. *Case.Rep.Transplant.* 2017;2017:3197042. doi: 10.1155/2017/3197042. Epub;2017 Dec 28.:3197042.
51. Roth A, Huttmann A, Rother RP, Duhrsen U, Philipp T. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. *Blood.* 2009;113:3885-3886.
52. Roth A, Duhrsen U. Cold agglutinin disease. *Eur.J.Haematol.* 2010;84:91.
53. Bommer M, Höchsmann B, Flegel W, Döhner H, Schrezenmeier H. Successful treatment of complement mediated refractory hemolysis associated with cold and warm autoantibodies using eculizumab. [abstract]. *Haematologica* 2011;94(suppl.2):241 abs. 0593.
54. Röth A, Bommer M, Hüttmann A et al. Complement Inhibition with Eculizumab in Patients with Cold Agglutinin Disease (CAD): Results from a Prospective Phase II Trial (DECADE Trial) [abstract]. *Blood* 2016;126:274.
55. Dumas G, Habibi A, Onimus T et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. *Blood.* 2016;127:1062-1064.
56. Boonyasampant M, Weitz IC, Kay B et al. Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. *Transfusion.* 2015;55:2398-2403.
57. Gupta S, Fennes A, Nance ST, Sykes DB, Dzik WS. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab. *Transfusion.* 2015;55:623-628.
58. Anliker M, Schmidt CQ, Harder MJ et al.: Complement activation by human anti-red cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay. *Transfusion* In press.
59. Sheridan D, Yu ZX, Zhang Y et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. *PLoS.ONE.* 2018;13:e0195909.
60. Lee JW, Rottinghaus ST, Lee LW et al. Results from a phase 3, multicenter, noninferiority study of ravalizumab (ALXN1210) versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria (PNH) naive to complement inhibitors [abstract]. *EHA Learning Center* 2018;Jun 17, 2018; 218885:
61. Fukuzawa T, Sampei Z, Haraya K et al. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. *Sci.Rep.* 2017;7:1080.
62. Nunn MA, Sharma A, Paesen GC et al. Complement inhibitor of C5 activation from the soft tick *Ornithodoros moubata*. *J.Immunol.* 2005;174:2084-2091.
63. Hill A, Wyndiga J, Robak T, Hellman J, Kulasekararaj A. RESULTS OF COBALT, A PHASE II CLINICAL TRIAL OF COVERSIN IN PNH [abstract]. *EHA Learning Center* 2018;Jun 15, 2018; 214790:
64. Ricardo A, Arata M, DeMarco S. Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria [abstract]. *Blood* 2015;126:939.
65. Hill A, Schrezenmeier H, Hillmen P, Szer J, Pullon H. RA101495, a subcutaneously administered peptide inhibitor of complement component C5, for the treatment of paroxysmal nocturnal hemoglobinuria: phase 2 results [abstract]. *EHA Learning Center.* 2018;Jun. 15, 2018; 214782:
66. Hill A, Valls AG, Griffin M, Munir T, Borodovsky A. A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Preliminary Phase 1/2 Study Results in Patients with PNH [abstract]. *Blood* 2016;128:3891:

67. Derhaschnig U, Gilbert J, Jager U et al. Combined integrated protocol/basket trial design for a first-in-human trial. *Orphanet.J.Rare.Dis.* 2016;11:134.
68. Jäger U, Gilbert JC, Panicker S. The anti C1s complement antibody TNT009 induces rapid complete remissions of anaemia in patients with primary cold agglutinin disease [abstract]. EHA Learning Center 2018;Jun 12, 2016; 135348:
69. Yuan X, Gavriilaki E, Thanassi JA et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. *Haematologica* 2017;102:466-475.
70. Risitano AM, Notaro R, Pascariello C et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. *Blood* 2012;119:6307-6316.
71. Risitano ASM, Sahelijo L. Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients [abstract]. *Blood* 2015;126:2137.
72. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. *J.Immunol.* 1996;157:884-891.
73. Apellis Pharma. Apellis Pharmaceuticals Provides Update on Two Phase Ib Trials for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). 2018. 1-7-2018.  
<http://investors.apellis.com/news-releases/news-release-details/apellis-pharmaceuticals-provides-update-two-phase-ib-trials>
74. Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. *Curr.Opin. Infect.Dis.* 2016;29:319-329.